Aurileya de Jesus Gouveia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurileya de Jesus Gouveia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Bioni Garcia Teles
Fundação Oswaldo Cruz image/svg+xml
3 shared publications - Amália dos Santos Ferreira
Unidade Rondônia, Brasil; Programa de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal - BIONORTE, Brasil; Fundação Universidade Federal de Rondônia/Fiocruz Rondônia, Brasil
2 shared publications - Minelly Azevedo da Silva
INSTITUTO FEDERAL DE EDUCAÇÃO, CIÊNCIA E TECNOLOGIA DE RONDÔNIA
2 shared publications - Ana Paula de Azevedo dos Santos
Plataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz-Rondônia (FIOCRUZ-RO), Porto Velho, RO, Brazil
1 shared publication - Carlos Roland Kaiser
LaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil
1 shared publication - Cristiane Diniz
LaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Universidade Federal da Bahia in Cadernos de Prospecção
- Vol. 19 (2) , 513-523
Prospecção Tecnológica de Patentes sobre Extratos Vegetais para Leishmaniose Cutânea: lacunas e oportunidades de inovação
A leishmaniose cutânea (LC) é uma doença negligenciada com elevada incidência no Brasil, e a biodiversidade representa fonte pouco explorada para terapias inovadoras. Apesar da relevância epidemiológica e dos avanços com extratos vegetais, existe uma lacuna entre a produção científica e a proteção intelectual, refletida no baixo número de patentes, sobretudo nacionais. Este estudo objetivou: (i) mapear patentes sobre extratos vegetais no tratamento da LC; (ii) identificar lacunas tecnológicas e oportunidades de inovação; e (iii) propor estratégias para fortalecer a proteção intelectual de ativos naturais. A metodologia consistiu em prospecção tecnológica nas bases INPI, Espacenet e Patentscope (2008-2025), com descritores e códigos IPC/CPC. As patentes foram triadas por relevância terapêutica, exclusão de duplicatas e categorização. Foram identificadas 18 patentes, três no INPI, com predominância de formulações tópicas. Os resultados evidenciam descompasso entre produção acadêmica e proteção intelectual, além da sub-representação da biodiversidade brasileira, reforçando a importância de políticas integradas.
- 1 April 2026
- Published by Universidade Federal da Bahia in Cadernos de Prospecção
- Vol. 19 (2) , 513-523
Open AccessProspecção Tecnológica de Patentes sobre Extratos Vegetais para Leishmaniose Cutânea: lacunas e oportunidades de inovação
A leishmaniose cutânea (LC) é uma doença negligenciada com elevada incidência no Brasil, e a biodiversidade representa fonte pouco explorada para terapias inovadoras. Apesar da relevância epidemiológica e dos avanços com extratos vegetais, existe uma lacuna entre a produção científica e a proteção intelectual, refletida no baixo número de patentes, sobretudo nacionais. Este estudo objetivou: (i) mapear patentes sobre extratos vegetais no tratamento da LC; (ii) identificar lacunas tecnológicas e oportunidades de inovação; e (iii) propor estratégias para fortalecer a proteção intelectual de ativos naturais. A metodologia consistiu em prospecção tecnológica nas bases INPI, Espacenet e Patentscope (2008-2025), com descritores e códigos IPC/CPC. As patentes foram triadas por relevância terapêutica, exclusão de duplicatas e categorização. Foram identificadas 18 patentes, três no INPI, com predominância de formulações tópicas. Os resultados evidenciam descompasso entre produção acadêmica e proteção intelectual, além da sub-representação da biodiversidade brasileira, reforçando a importância de políticas integradas.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 19 (6) , 1
Synthesis of New Bi-Triazoles with Plasmocide Action Against Plasmodium falciparum
Background: A series of bi-triazoles conjugates 1,2,3 and 1,2,4 was synthesized with an aim to study the evaluation of the antimalarial profile of families of triazole derivatives. The study used the W2 strain of Plasmodium falciparum (Chloroquine-Resistant), to determine the inhibitory concentration of 50% of the parasites (IC50) and HepG2 cells to describe the cytotoxic concentration for 50% of the cells (CC50). Among the study classes, bi-triazoles stood out with IC50 values between 8.9 to 0.45 μM; highlighted the compound 14d (IC50 of 0.45 ± 0.02 μM) with the most promising result. Regarding the cytotoxic concentration, all compounds that presented IC50 values ≤ 100 μM were evaluated. Three compounds stood out as the highest selectivity index (SI) values, 14b (SI ˃111.1), 13d (SI ˃111.1) and 14d (SI ˃1.111). Such results expose the importance of working with classes of molecules that allow rapid synthesis and dispositions for structural changes. Highlighting the evolution of the IC50 values of the compounds, when adding the second triazole block. Thus, the results found in this study, have the possibility of choosing new molecules for the treatment of malaria. Objective: This work was to synthesize a series of bi-triazole conjugates 1,2,3 and 1,2,4-triazole moiety and evaluate their activities against Plasmodium falciparum. Methods: The bi-triazole was synthesized in a 3-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. For the in vitro antiplasmodial assays, the SYBR Green fluorimetric technique and the W2 strain were used, where an IC50 (Inhibitory Concentration) value was obtained for each compound. The compounds were also evaluated for their stagespecificity and speed of action (W2 strain). Safety tests were performed to determine the hemolytic and cytotoxic action of the evaluated compounds. In these tests, the cell lines HepG2 and VERO were used, and the cytotoxicity was evaluated by the MTT technique. This allowed the CC50 values to be obtained (Cytotoxic Concentration). Subsequently, the Selectivity Index (SI) was calculated for each compound. Results: The newly synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial compounds. In general, the bi-triazoles with trifluoromethyl group present at 1,2,4-triazole moiety proved to be more potent regarding antiplasmodial activity. Conclusion: The synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial agents.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 19 (6) , 1
Synthesis of New Bi-Triazoles with Plasmocide Action Against Plasmodium falciparum
Background: A series of bi-triazoles conjugates 1,2,3 and 1,2,4 was synthesized with an aim to study the evaluation of the antimalarial profile of families of triazole derivatives. The study used the W2 strain of Plasmodium falciparum (Chloroquine-Resistant), to determine the inhibitory concentration of 50% of the parasites (IC50) and HepG2 cells to describe the cytotoxic concentration for 50% of the cells (CC50). Among the study classes, bi-triazoles stood out with IC50 values between 8.9 to 0.45 μM; highlighted the compound 14d (IC50 of 0.45 ± 0.02 μM) with the most promising result. Regarding the cytotoxic concentration, all compounds that presented IC50 values ≤ 100 μM were evaluated. Three compounds stood out as the highest selectivity index (SI) values, 14b (SI ˃111.1), 13d (SI ˃111.1) and 14d (SI ˃1.111). Such results expose the importance of working with classes of molecules that allow rapid synthesis and dispositions for structural changes. Highlighting the evolution of the IC50 values of the compounds, when adding the second triazole block. Thus, the results found in this study, have the possibility of choosing new molecules for the treatment of malaria. Objective: This work was to synthesize a series of bi-triazole conjugates 1,2,3 and 1,2,4-triazole moiety and evaluate their activities against Plasmodium falciparum. Methods: The bi-triazole was synthesized in a 3-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. For the in vitro antiplasmodial assays, the SYBR Green fluorimetric technique and the W2 strain were used, where an IC50 (Inhibitory Concentration) value was obtained for each compound. The compounds were also evaluated for their stagespecificity and speed of action (W2 strain). Safety tests were performed to determine the hemolytic and cytotoxic action of the evaluated compounds. In these tests, the cell lines HepG2 and VERO were used, and the cytotoxicity was evaluated by the MTT technique. This allowed the CC50 values to be obtained (Cytotoxic Concentration). Subsequently, the Selectivity Index (SI) was calculated for each compound. Results: The newly synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial compounds. In general, the bi-triazoles with trifluoromethyl group present at 1,2,4-triazole moiety proved to be more potent regarding antiplasmodial activity. Conclusion: The synthesized bi-triazole compounds could serve as potent leads for the development of novel antimalarial agents.
- 1 January 2022
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
- Vol. 33 (5) , 483-490
Natural and Semisynthetic Triterpenes from Combretum leprosum Mart. with Antiplasmodial Activity
Malaria is responsible for thousands of deaths each year. Currently, artemisinin combination therapy (ACT) is used as first-choice medication against the disease. However, the emergence of resistant strains prompts the search for alternative compounds. The present study aimed to investigate the antiplasmodial activities of natural triterpenes (compounds 1 and 2), and semisynthetic derivatives 1a, 1b, 1c, and 1d. Antiplasmodial assays were carried out using the SYBR Green technique, whereas cytotoxicity was evaluated by the MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide) method. Hemolytic assays were performed on human erythrocytes. An in silico analysis of the compounds against PfENR (Plasmodium falciparum 2-trans-enoyl-reductase) was carried out by molecular docking. Experiments with 1, and its derivatives against P. falciparum showed that 1a was very similar in terms of biological activity to compound 1 (half maximal inhibitory concentration (IC50) ca. 4 μM), whereas 1b, 1c, and 1d had reduced antiplasmodial activities (IC50 between 8-103 μM). The selectivity indexes of 1 and 1d for HepG2, and Vero cells were > 10. Docking results partially agreed with the in vitro experiments, with 1 and 1c having the best and worst affinities with PfENR, respectively. In conclusion, the results showed that 1 and 1d may serve as biotechnological tools in the development of antimalarial drugs.
- 1 January 2022
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
- Vol. 33 (5) , 483-490
Natural and Semisynthetic Triterpenes from Combretum leprosum Mart. with Antiplasmodial Activity
Malaria is responsible for thousands of deaths each year. Currently, artemisinin combination therapy (ACT) is used as first-choice medication against the disease. However, the emergence of resistant strains prompts the search for alternative compounds. The present study aimed to investigate the antiplasmodial activities of natural triterpenes (compounds 1 and 2), and semisynthetic derivatives 1a, 1b, 1c, and 1d. Antiplasmodial assays were carried out using the SYBR Green technique, whereas cytotoxicity was evaluated by the MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide) method. Hemolytic assays were performed on human erythrocytes. An in silico analysis of the compounds against PfENR (Plasmodium falciparum 2-trans-enoyl-reductase) was carried out by molecular docking. Experiments with 1, and its derivatives against P. falciparum showed that 1a was very similar in terms of biological activity to compound 1 (half maximal inhibitory concentration (IC50) ca. 4 μM), whereas 1b, 1c, and 1d had reduced antiplasmodial activities (IC50 between 8-103 μM). The selectivity indexes of 1 and 1d for HepG2, and Vero cells were > 10. Docking results partially agreed with the in vitro experiments, with 1 and 1c having the best and worst affinities with PfENR, respectively. In conclusion, the results showed that 1 and 1d may serve as biotechnological tools in the development of antimalarial drugs.